Cat. No.: HY-13406

TAK-779

(Synonyms: Takeda 779)

13 Cited Publications

Customer Review

Based on 13 publication(s) in Google Scholar

TAK-779 is a potent and selective nonpeptide antagonist of CCR5 and CXCR3, with a K_i of 1.1 nM for CCR5, and effectively and selectively inhibits R5 HIV-1, with EC₅₀ and EC₉₀ of 1.2 nM and 5.7 nM, respectively, in MAGI-CCR5 cells.

For research use only. We do not sell to patients.

Purity: 99.89%
CAS No.: 229005-80-5
Formula: C₃₃H₃₉ClN₂O₂
Molecular Weight:531.13

Storage:

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

TAK-779 Chemical Structure

CAS No.: 229005-80-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (13)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]^[4]

MIP-1α-CCR5

1 nM (IC₅₀, in CHO/CCR5 cells)

MIP-1β-CCR5

1 nM (IC₅₀, in CHO/CCR5 cells)

RANTES-CCR5

1.4 nM (IC₅₀, in CHO/CCR5 cells)

MCP-1-CCR2b

27 nM (IC₅₀, in CHO/CCR5 cells)

R5 HIV-1 (Ba-L)

1.2 nM (EC₅₀, in MAGI-CCR5 cells)

R5 HIV-1 (KK)

1.6 nM (EC₅₀, in PBMCs)

R5 HIV-1 (HHA)

3.2 nM (EC₅₀, in PBMCs)

R5 HIV-1 (CTV)

3.5 nM (EC₅₀, in PBMCs)

R5 HIV-1 (Ba-L)

3.7 nM (EC₅₀, in PBMCs)

R5 HIV-1 (Ba-L)

5.7 nM (EC90, in MAGI-CCR5 cells)

R5 HIV-1 (HHA)

7.5 nM (EC90, in PBMCs)

R5 HIV-1 (Ba-L)

12.8 nM (EC90, in PBMCs)

R5 HIV-1 (KK)

20.8 nM (EC90, in PBMCs)

R5 HIV-1 (CTV)

27 nM (EC90, in PBMCs)

mCXCR3

369 nM (IC₅₀, in PBMCs)

All CCR Isoforms :

All HIV Isoforms :

All CXCR Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	>10 μM Compound: 1r, TAK-779	Inhibitory effect on the binding of [125I]- eotaxin to C-C chemokine receptor type 3- expressing CHO cells Inhibitory effect on the binding of [125I]- eotaxin to C-C chemokine receptor type 3- expressing CHO cells	[PMID: 10821717]
CHO	IC₅₀	>10 μM Compound: 1r, TAK-779	Inhibitory effect on the binding of [125I]RANTES to C-C chemokine receptor type 1-expressing CHO cells Inhibitory effect on the binding of [125I]RANTES to C-C chemokine receptor type 1-expressing CHO cells	[PMID: 10821717]
CHO	IC₅₀	>10 μM Compound: 1r, TAK-779	Inhibitory effect on the binding of [125I]TARC to C-C chemokine receptor type 4-expressing CHO cells Inhibitory effect on the binding of [125I]TARC to C-C chemokine receptor type 4-expressing CHO cells	[PMID: 10821717]
CHO	IC₅₀	0.027 μM Compound: 1r, TAK-779	Inhibitory effect on the binding of [125I]- MCP-1 to C-C chemokine receptor type 2-expressing CHO cells Inhibitory effect on the binding of [125I]- MCP-1 to C-C chemokine receptor type 2-expressing CHO cells	[PMID: 10821717]
CHO	IC₅₀	1.4 nM Compound: 1	Displacement of [125I]RANTES from CCR5 expressed in CHO cells Displacement of [125I]RANTES from CCR5 expressed in CHO cells	[PMID: 16539392]
CHO	IC₅₀	1.4 nM Compound: 2	Inhibition of [125I]RANTES association with CCR5 expressed in CHO cells at 100 nM Inhibition of [125I]RANTES association with CCR5 expressed in CHO cells at 100 nM	[PMID: 11931608]
CHO	IC₅₀	1.4 nM Compound: TAK-779	Inhibition of CCL5 binding to CCR5 expressed in CHO cells Inhibition of CCL5 binding to CCR5 expressed in CHO cells	[PMID: 21820898]
CHO	IC₅₀	28 nM Compound: 1, TAK-779	Displacement of [125I]hMCP1 from human CCR2 receptor expressed in CHO cells Displacement of [125I]hMCP1 from human CCR2 receptor expressed in CHO cells	[PMID: 19237282]
CHO-K1	IC₅₀	0.03 nM Compound: TAK-779	Displacement of [125I]MCP1 from CCR2/CXCR4 expressed in CHOK1 cells Displacement of [125I]MCP1 from CCR2/CXCR4 expressed in CHOK1 cells	[PMID: 17715128]
CHO-K1	IC₅₀	0.08 nM Compound: TAK-779	Displacement of [125I]SDF1alpha from CCR2/CXCR4 expressed in CHOK1 cells Displacement of [125I]SDF1alpha from CCR2/CXCR4 expressed in CHOK1 cells	[PMID: 17715128]
CHO-K1	IC₅₀	0.25 nM Compound: TAK-779	Displacement of [125I]MCP1 from CCR2 expressed in CHOK1 cells Displacement of [125I]MCP1 from CCR2 expressed in CHOK1 cells	[PMID: 17715128]
COS-7	IC₅₀	1.4 nM Compound: 1	Inhibition of membrane fusion between HIV1 JR-FL Env-expressing COS7 cells and MOLT4/CCR5 Inhibition of membrane fusion between HIV1 JR-FL Env-expressing COS7 cells and MOLT4/CCR5	[PMID: 16539392]
HEK-293T	EC₅₀	7 nM Compound: 1; TAK-779	Positive allosteric modulation of human CCR5 expressed in HEK293T cells co-expressing CAMYEL assessed as increase in CCL4-induced inhibition of forskolin-stimulated cAMP accumulation after 10 mins by BRET assay Positive allosteric modulation of human CCR5 expressed in HEK293T cells co-expressing CAMYEL assessed as increase in CCL4-induced inhibition of forskolin-stimulated cAMP accumulation after 10 mins by BRET assay	[PMID: 28463783]
MOLT-4	IC₅₀	7.9 nM Compound: TAK-779	Antagonist activity at human CCR5 receptor expressed in MOLT4/CCR5 cells assessed as inhibition of CCL5-induced intracellular calcium mobilization by spectrophotometry Antagonist activity at human CCR5 receptor expressed in MOLT4/CCR5 cells assessed as inhibition of CCL5-induced intracellular calcium mobilization by spectrophotometry	[PMID: 21820898]
PC-3	IC₅₀	37.85 μM Compound: 2, TAK-779	Antiproliferative activity against human PC3 cells after 72 hrs by WST-1 assay Antiproliferative activity against human PC3 cells after 72 hrs by WST-1 assay	[PMID: 24731275]
U2OS	IC₅₀	23 μM Compound: TAK779	Antagonist activity against mouse CCR2B expressed in human U2OS cells co-expressing beta-arrestin assessed as inhibition of mouse CCL2-induced beta-arrestin recruitment pre-incubated for 10 mins before mouse CCL2 stimulation for 90 mins by luminescence ba Antagonist activity against mouse CCR2B expressed in human U2OS cells co-expressing beta-arrestin assessed as inhibition of mouse CCL2-induced beta-arrestin recruitment pre-incubated for 10 mins before mouse CCL2 stimulation for 90 mins by luminescence ba	[PMID: 25766632]
U2OS	IC₅₀	6 nM Compound: TAK-779	Antagonist activity at human TEV cleavage site-linked CCR5 expressed in human U2OS cells harboring beta-lactamase reporter gene assessed as inhibition of CCL3-induced beta-arrestin recruitment incubated for 30 mins followed by CCL3 stimulation and measure Antagonist activity at human TEV cleavage site-linked CCR5 expressed in human U2OS cells harboring beta-lactamase reporter gene assessed as inhibition of CCL3-induced beta-arrestin recruitment incubated for 30 mins followed by CCL3 stimulation and measure	[PMID: 31742400]

In Vitro

TAK-779 is a potent and selective nonpeptide antagonist of CCR5, with a K_i of 1.1 nM, and effectively and selectively inhibits R5 HIV-1, with EC₅₀ and EC₉₀ of 1.2 nM and 5.7 nM, respectively, in MAGI-CCR5 cells. TAK-779 less potently blocks the binding of [¹²⁵I]-monocyte chemotactic protein 1 to CCR2b in CHO/CCR2b cells, with an IC₅₀ for CCR2b of 27 nM. TAK-779 also completely inhibits the binding of [¹²⁵I]-RANTES to CHO/CCR5 cells with an IC₅₀ of 1.4 nM. TAK-779 (20 nM) selectively inhibits CCR5-mediated Ca²⁺-signaling. In addition, TAK-779 shows no inhibition on X4 HIV-1 strains^[1]. TAK-779 is an antagonist of CXCR3, and inhibits the migration of T cells but not T cell proliferation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

TAK-779 (10 mg/kg per day, s.c.) significantly prolongs the allograft survival of the rat intestinal transplantation model. TAK-779 also decreases the number of CD4⁺ as well as CD8⁺ T cells in spleen, blood and recipient mesenteric lymph nodes (MLN)^[2]. TAK-779 (150 μg per mouse, s.c.) supppresses the development of experimental autoimmune encephalomyelitis (EAE) in myelin oligodendrocyte glycoprotein (MOG)-immunized C57BL/6 mice. TAK-779 decreases the infiltration of CXCR3 and CCR5 bearing leukocytes into the spinal cord. TAK-779 does not alter myelin oligodendrocyte glycoprotein (MOG)-specific immune responses or affect the potential of MOG-specific T cells to transfer experimental autoimmune encephalomyelitis (EAE)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 229005-80-5
Appearance Solid
Molecular Weight 531.13
Formula C₃₃H₃₉ClN₂O₂
Color White to off-white
SMILES

C[N+](C)(CC1=CC=C(NC(C2=CC3=CC(C4=CC=C(C)C=C4)=CC=C3CCC2)=O)C=C1)C5CCOCC5.[Cl-]
Synonyms

Takeda 779
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

Publications (13)

All Cell Migration/Invasion AssayRT-PCRCell Imaging/StainingHistological Imaging/Staining

Sort by:

Journal Impact Factor

Nature

EBV induces CNS homing of B cells attracting inflammatory T cells. [Abstract]

2025 Oct;646(8083):171-179. PMID: 40770101

TAK-779 purchased from MedChemExpress. Usage Cited in: Nature. 2025 Oct;646(8083):171-179. [Abstract]

Transwell migration assays with supernatant from LCLs with CCL3, CCL4 and CCL5 neutralizing antibodies or a CXCR3 and CCR5 antagonist (TAK-779: 3 μM).
Immunity

Spatiotemporal dynamics of CXCL10 encode contextual immune information revealed by the genetically encoded fluorescent sensor. [Abstract]

2025 Sep 9;58(9):2320-2335.e9. PMID: 40818452
Adv Sci (Weinh)

Repurposing of Chemokine Antagonists for Combined Phase-Resolved Spinal Cord Injury Treatment. [Abstract]

2025 Oct 28:e16569. PMID: 41147460

TAK-779 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 28:e16569. [Abstract]

TAK-779 (2 mg/kg). Representative spinal cord MRI images of the injured segments in SD rats from the treated and untreated groups. High-signal and low-signal areas are indicated in red and blue, respectively.

TAK-779 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 28:e16569. [Abstract]

TAK-779 (2 mg/kg). Representative histological structures of spinal cord injury sites in SD rats treated with the specified therapy were assessed using hematoxylin-eosin staining, hedenhain staining, and anti-GFAP staining, and compared with untreated SD rats.
Sci Adv

Overcoming host restrictions to enable continuous passaging of GII.3 human norovirus in human intestinal enteroids. [Abstract]

2026 Feb 6;12(6):eaeb0455. PMID: 41637508

TAK-779 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2026 Feb 6;12(6):eaeb0455. [Abstract]

HIEs were pretreated for 3 hours with the indicated concentrations of TAK-779 and then infected with GII.3 HuNoV (2.9 × 105 GEs per well) in the absence or presence of the same concentrations of TAK-779. After washing, the cells were cultured for 48 hours at 37°C in the absence or presence of TAK-779. Viral GEs at 1 and 48 hours postinfection were quantified by RT-qPCR.

TAK-779 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2026 Feb 6;12(6):eaeb0455. [Abstract]

TAK-779 (15/30 μM). Monolayers of cells were fixed with methanol at 24 and 48 hours post-infection. GII.3 positive cells (green) were detected using guinea pig anti-human norovirus VLP antibody (green), and cell nuclei were detected using DAPI (blue). Representative images of each group at 48 hours post-infection are shown.
Redox Biol

PP4 modulates macrophage-neutrophil crosstalk to restrict CCL5 -driven NETosis in sepsis. [Abstract]

2026 Apr:91:104093. PMID: 41723906
Cell Death Dis

FGFR4 promotes CAF activation through the CXCL10-CXCR3 axis in colon cancer. [Abstract]

2025 May 30;16(1):424. PMID: 40447617
Front Pharmacol

CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome. [Abstract]

2024 Feb 21:15:1351655. PMID: 38449806
J Cell Mol Med

HIF-1α is necessary for activation and tumour-promotion effect of cancer-associated fibroblasts in lung cancer. [Abstract]

2021 Jun;25(12):5457-5469. PMID: 33943003
J Virol

2026 May 11.
Front Biosci (Landmark Ed)

A Comparative Study of the Effects of Nine CXCR3 Antagonists on Macrophage Function and the Treatment of Acute Lung Injury. [Abstract]

2025 Oct 31;30(10):45931. PMID: 41198562
Albert Einstein College of Medicine

2026.
bioRxiv

Glypican-1 upregulation elicited in response to a cell-impermeable kinase inhibitor and its overexpression enhance HIV-1 infection. [Abstract]

2025 Oct 28:2025.10.28.685002. PMID: 41278678
bioRxiv

Overcoming host restrictions to enable continuous passaging of human noroviruses in human intestinal enteroids. [Abstract]

2025 May 22:2025.05.22.655571. PMID: 40661516

Solvent & Solubility

In Vitro:

DMSO : ≥ 25 mg/mL (47.07 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 5 mg/mL (9.41 mM; ultrasonic and warming and heat to 60°C)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8828 mL

9.4139 mL

18.8278 mL

5 mM

0.3766 mL

1.8828 mL

3.7656 mL

10 mM

0.1883 mL

0.9414 mL

1.8828 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.58 mg/mL (4.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.58 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.58 mg/mL (4.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.58 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.58 mg/mL (4.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.58 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 50 mg/mL (94.14 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[1]

The anti-HIV-1 activities of the test compounds (TAK-779, etc.) are based on the inhibition of virus-induced infectious focus formation in MAGI-CCR5 cells and the reduction of p24 antigen production in PBMCs. In brief, MAGI-CCR5 cells (1 × 10⁴ cells per well) are cultured in a microtiter tray. After a 24-h incubation at 37°C, the culture supernatants are replaced with fresh culture media containing the virus (≈300 focus forming units per well) and various concentrations of the test compounds (TAK-779, etc.). After a 2-day incubation, the cells are fixed and stained with 5-bromo-4-chloro-3-indolyl-β-d-galactosidase. The number of infected (blue) cells is counted microscopically. For the PBMC assays, phytohemagglutinin-stimulated PBMCs (2.5 × 10⁵ cells per 500 μl) are infected with HIV-1 in the presence of various concentrations of the test compounds (TAK-779, etc.). The amounts of the virus used for infection are, depending on the replicability of each strain, generally 1-10 ng of p24 per 2.5 × 10⁵ cells. After an overnight incubation at 37°C, the cells are washed extensively to remove unadsorbed viral particles and are incubated further with culture media containing the same concentrations of the compounds as those used during viral adsorption. On day 6 after viral infection, the culture supernatants are collected and determined for their p24 antigen levels with a sandwich ELISA kit. The cytotoxicities of the compounds are evaluated in parallel with their antiviral activities. They are based on the viability and proliferation of mock-infected cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

Mice^[3]
The mice are immunized with MOG and are treated s.c. with TAK-779 or vehicle. The mice (N= 10) are injected s.c. with 150 µg TAK-779 (dissolved in 5% mannitol solution) in a volume of 100 µL, once daily after MOG immunization. TAK-779 injection is started from day 0 after immunization and continued once daily for 22 days. The dose of 150 µg is determined based on the observations in prior experiments that the dose of 50 µg per mouse can not produce inhibition, and a dose of more than 100 µg per mouse is required to produce significant inhibition. The dose of 150 µg per mouse has also been used in other mouse experimental models, and approximately the same dose is used in allograft rejection and asthma models. As a control, an equal volume of PBS containing 5% mannitol is injected daily in the control mice (N= 10)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Baba M, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A. 1999 May 11;96(10):5698-703. [Content Brief]

[2]. Takama Y, et al. Effects of a calcineurin inhibitor, FK506, and a CCR5/CXCR3 antagonist, TAK-779, in a rat small intestinal transplantation model. Transpl Immunol. 2011 Jul;25(1):49-55. [Content Brief]

[3]. Ni J, et al. The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function. Br J Pharmacol. 2009 Dec;158(8):2046-56. [Content Brief]

[4]. Gao P, et al. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol. 2003 Feb;73(2):273-80. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.8828 mL	9.4139 mL	18.8278 mL	47.0695 mL
H₂O / DMSO	5 mM	0.3766 mL	1.8828 mL	3.7656 mL	9.4139 mL
DMSO	10 mM	0.1883 mL	0.9414 mL	1.8828 mL	4.7069 mL
	15 mM	0.1255 mL	0.6276 mL	1.2552 mL	3.1380 mL
	20 mM	0.0941 mL	0.4707 mL	0.9414 mL	2.3535 mL
	25 mM	0.0753 mL	0.3766 mL	0.7531 mL	1.8828 mL
	30 mM	0.0628 mL	0.3138 mL	0.6276 mL	1.5690 mL
	40 mM	0.0471 mL	0.2353 mL	0.4707 mL	1.1767 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

TAK-779

Anti-Infection Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Antiviral Compound Library

Small Molecule Immuno-Oncology Compound Library

Covalent Screening Library

Endocrinology Compound Library

Anti-Pulmonary Fibrosis Compound Library

Chemokine Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) TAK-779

All CCR Isoforms

All HIV Isoforms

All CXCR Isoforms

Biological Activity

Chemical Information

Publications (13)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

TAK-779

Anti-Infection Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Antiviral Compound Library

Small Molecule Immuno-Oncology Compound Library

Covalent Screening Library

Endocrinology Compound Library

Anti-Pulmonary Fibrosis Compound Library

Chemokine Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) TAK-779

All CCR Isoforms

All HIV Isoforms

All CXCR Isoforms

Biological Activity

Chemical Information

Publications (13)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

TAK-779 Related Classifications

HY-13406 Related Classifications